Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Vanguard Ultra Short Bond ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.55 (market cap $5.07B), while Vanguard Ultra Short Bond ETF trades at $49.67. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Vanguard Ultra Short Bond ETF nearer its low. Which is the better fit depends on your goals.
| ACAD | VUSB | |
|---|---|---|
Market Cap | $5.07B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $29.41 | $50.03 |
52-Week Low | $20.06 | $49.60 |
Enterprise Value | $4.19B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
